

IN THE CLAIMS:

Claims 1-93. (canceled).

94. (Currently amended) A transgenic mouse comprising ~~a recombinant cell,~~
~~wherein said cell comprises a~~ an exogenous nucleotide sequence, wherein said exogenous
nucleotide sequence comprises a Group I intron encoded endonuclease recognition site,
wherein the site is selected from the group consisting of an I-*SceIV* site, an I-*CsmI* site, I-*PanI* site, I-*SceII* site, an I-*CeuI* site, an I-*PpoI* site, an I-*SceIII* site, an I-*CreI* site, an I-*TevI* site, an I-*TevII* site, an I-*TevIII* site, and an I-*SceI* site.

95. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*SceIV* site.

96. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*CsmI* site.

97. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*PanI* site.

98. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*SceII* site.

99. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*CeuI* site.

100. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*PpoI* site.

101. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*SceIII* site.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

102. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*CreI* site.

103. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*TevI* site.

104. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*TevII* site.

105. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*TevIII* site.

106. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-*SceI* site.

107. (Currently amended) A method of culturing transgenic cells comprising the steps of:

(a) providing a cell from a transgenic mouse comprising an exogenous nucleotide sequence, wherein said exogenous nucleotide sequence comprises ~~in which~~ at least one Group I intron encoded endonuclease recognition site ~~is inserted at a unique location in a chromosome of said cell,~~

wherein the site is selected from the group consisting of an I-*SceIV* site, an I-*CsmI* site, I-*PanI* site, I-*SceII* site, an I-*CeuI* site, an I-*PpoI* site, an I-*SceIII* site, an I-*CreI* site, an I-*TevI* site, an I-*TevII* site, an I-*TevIII* site, and an I-*SceI* site; and

(b) culturing said cell under conditions that allow growth of said cell.

108. (Previously presented) The method of claim 107, wherein the site is an I-*SceIV* site.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

109. (Previously presented) The method of claim 107, wherein the site is an I-*CsmI* site.
110. (Previously presented) The method of claim 107, wherein the site is an I-*PanI* site.
111. (Previously presented) The method of claim 107, wherein the site is an I-*SceII* site.
112. (Previously presented) The method of claim 107, wherein the site is an I-*CeuI* site.
113. (Previously presented) The method of claim 107, wherein the site is an I-*PpoI* site.
114. (Previously presented) The method of claim 107, wherein the site is an I-*SceIII* site.
115. (Previously presented) The method of claim 107, wherein the site is an I-*CreI* site.
116. (Previously presented) The method of claim 107, wherein the site is an I-*TevI* site.
117. (Previously presented) The method of claim 107, wherein the site is an I-*TevII* site.
118. (Previously presented) The method of claim 107, wherein the site is an I-*TevIII* site.
119. (Previously presented) The method of claim 107, wherein the site is an I-*SceI* site.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com